logo
If you think you'll never need long-term care, you're probably wrong

If you think you'll never need long-term care, you're probably wrong

Yahoo29-01-2025
If you think you've saved enough for retirement, you may not be thinking about long-term care.
The long-term care industry serves people who cannot perform everyday activities, like dressing or eating, without help. More than 80% of Americans will need that help at some point, according to a new study from the Center for Retirement Research at Boston College.
The costs of long-term care can be staggering. Hire a home health aide for 40 hours a week, and you'll pay $5,720 a month, on average, according to a new report from T. Rowe Price, the investment firm. An assisted living facility charges $5,350 a month. A nursing home will run you $9,733.
Many Americans have watched long-term care play out for a parent or grandparent. But many of us seem to be in denial about whether we might need long-term care ourselves, and about what it costs.
'People tend to underestimate how much long-term care they're going to need, and when they're going to need it,' said Gal Wettstein, a senior research economist at Boston College.
In one 2024 survey of affluent older Americans, Boston College researchers found, long-term care ranked fifth among financial worries in retirement, behind stock market turbulence, Social Security cuts and other concerns.
Many older Americans are badly misinformed about the finances of long-term care. In another survey, Boston College reports, 45% of seniors said they believed Medicare covers long-term care. That's mostly untrue.
It's hard to plan for long-term care, because the costs can range from nothing to millions of dollars.
'Long-term care represents one of the most significant and unpredictable risks we face,' said Laura Mattia, a certified financial planner in Sarasota, Florida.
If you are 65 today, there is a nearly 40% chance that you will need 'high-intensity' long-term care, such as a nursing-home stay, for at least a year, according to Boston College research. There's an 18% chance you'll need high-intensity care for three or more years. That could easily be a six-figure expense.
But at least half of all seniors have no retirement account, according to federal data.
In fact, roughly two-thirds of all long-term care in America is 'informal and unpaid,' T. Rowe Price reports, delivered by spouses, children and other relatives.
'Family caregivers are really the backbone of our long-term care system,' said Debra Whitman, chief public policy officer at AARP.
And therein lies some good news. Because of family care and other factors, most Americans spend very little from their own pockets on long-term care.
Long-term care spending totaled $467 billion in 2021, the most recent data available in the T. Rowe Price report. Government programs covered 71% of those costs: chiefly, Medicaid and Medicare. Only 14% of long-term care spending was out of pocket.
But counting on either Medicaid or loved ones to deliver long-term care is not ideal. Leaning on loved ones can pose an unfair burden. And Medicaid generally kicks in only when all of your assets run out, potentially leaving nothing for your heirs.
'I don't know anybody who wants [Medicaid] to be their first option,' said Justin Cleveland, a wealth management advisor at Northwestern Mutual's Belvin, Cleveland & Associates in Dallas.
Studies repeatedly show that most Americans don't have a plan for long-term care.
In a 2024 survey by Northwestern Mutual, 63% of Generation X and 50% of boomers acknowledged they would probably need long-term care. But well under half of respondents in each group said they had a financial plan to cover that care.
Long-term care insurance is not cheap, and the industry has contracted in recent years. But many financial planners recommend it to their clients, especially those who want to pass wealth to their heirs.
'The industry has come a long way,' said Catherine Valega, a certified financial planner in Winchester, Massachusetts.
Many people never consider long-term care insurance. Only about 15% of seniors hold policies, according to AARP.
But shopping for long-term care insurance could make sense, especially if you are between ages 55 and 65, according to T. Rowe Price. Buying a policy earlier than that could expose you to costly premium hikes. If you wait till you are older, there's a higher chance your application will be denied over age or illness.
Policies come in a dizzying variety. Costs vary according to the dollar amount or length of care covered, and other variables. Some policies refund money to your heirs if the benefits aren't used.
Another option is to buy a life insurance policy with a long-term care rider, which allows you to use the death benefit to pay for long-term care.
'Depending on the insurer, this could be a more affordable way to have long-term care insurance,' said Andrew Herzog, a certified financial planner in Plano, Texas.
Rather than buy insurance, you can 'self-insure,' saving enough money to pay for long-term care. The problem is deciding how much to save.
To cover the costs of long-term care, you might need to save anywhere from $300,000 to $2.5 million or more, depending on the expert source.
'The numbers are so big, it's more than most people have saved over the course of their entire life,' said Whitman of AARP.
But those figures represent worst-case scenarios.
T. Rowe Price found that most seniors spend little of their own money on health care in their last years of life. Even among people who live past 90, only about 10% spend more than $100,000 out of pocket in their final two years.
'It is a small subset of people who are paying these massive expenses out of pocket,' said Lindsay Theodore, a certified financial planner at T. Rowe Price and co-author of the report. 'The dollar amounts aren't as crazy or unfathomable as people might think.'
This article originally appeared on USA TODAY: Think you won't need long-term care? You're probably wrong.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oppenheimer Reduces PT on UnitedHealth Group (UNH) Stock
Oppenheimer Reduces PT on UnitedHealth Group (UNH) Stock

Yahoo

time34 minutes ago

  • Yahoo

Oppenheimer Reduces PT on UnitedHealth Group (UNH) Stock

UnitedHealth Group Incorporated (NYSE:UNH) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 30, Oppenheimer analyst Michael Wiederhorn reduced the price objective on UnitedHealth Group Incorporated (NYSE:UNH)'s stock to $325 from $400, while keeping an 'Outperform' rating, as reported by The Fly. It noted that the company reinstated 2025 adjusted-EPS guidance of $16.00-plus, which can be trough earnings, as UnitedHealth Group Incorporated (NYSE:UNH) returns to growth in 2026 and beyond. A senior healthcare professional giving advice to a patient in a clinic. The 2025 guidance assumes performance at the bottom-end or below target ranges throughout Medicare, Medicaid, Commercial, and OptumHealth segments, though the firm opines that such metrics will improve significantly over the upcoming 2 years as UnitedHealth Group Incorporated (NYSE:UNH) re-prices its respective books. The company expects moderate EPS growth in 2026, with acceleration thereafter. UnitedHealth Group Incorporated (NYSE:UNH) has updated its 2025 outlook, which includes revenues of $445.5 billion – $448.0 billion, net earnings of at least $14.65 per share, and adjusted earnings of at least $16.00 per share. This implies H1 2025 performance and expectations for the balance of the year, including higher realized and anticipated care trends. Baron Funds, an investment management company, released its Q2 2025 investor letter. Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a diversified health and well being company with $450 billion in annual revenue, operating across four segments: UnitedHealthcare, Optum Health, Optum lnsight, and Optum Rx. Shares fell sharply during the quarter after the company missed earnings estimates and cut its 2025 earnings per share guidance, citing higher-than-expected medical costs in its Medicare Advantage business. Investor confidence was further shaken in early May by the abrupt departure of CEO Andrew Witty and the suspension of 2025 guidance. The company also mispriced its Medicare Advantage business for 2025—a challenge compounded by reimbursement changes and an influx of newly acquired members who had not been properly risk coded. While we acknowledge UnitedHealth's potential to restore profitability in this segment over time through disciplined pricing and benefit adjustments, we chose to exit our position during the quarter in favor of other opportunities. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template

Forbes

time43 minutes ago

  • Forbes

Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template

The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.

Saquon Barkley among NFL stars who will join President Trump's council on Sports Nutrition
Saquon Barkley among NFL stars who will join President Trump's council on Sports Nutrition

USA Today

time7 hours ago

  • USA Today

Saquon Barkley among NFL stars who will join President Trump's council on Sports Nutrition

Eagles running back Saquon Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trumps Council on Sports, Fitness, and Nutrition.' Saquon Barkley is a son, a fantastic father, the NFL's Offensive Player of the Year winner, and now a member of President Donald Trump's administration. In a move that will revive a standard from the Reagan, Clinton, and Bush era, Barkley will join Harrison Butker, Nick Bosa, Tony Romo, and Lawrence Taylor on President Trump's Council on Sports, Fitness, and Nutrition.' According to the Washington Post, President Trump on Thursday announced that the presidential fitness test, a hallmark of American physical education programs, will be making a comeback in public schools. The assessment was retired and replaced by a fitness program under the Obama administration. The presidential fitness test was initiated in the 1950s by a council established by President Dwight D. Eisenhower that was directed to improve the physical fitness of American youths, in response to fears they were falling behind their European counterparts when it came to athleticism. The project is an alternative way to get anti-obesity drugs to Medicare and Medicaid patients, after the administration said in April that neither program would cover GLP-1s for weight loss. In doing so, it scrapped a 2024 Biden administration proposal for the programs to start covering GLP-1s for patients with obesity. Several high-profile athletes — all of whom have existing ties to Trump — attended the ceremony and will serve on the President's Council on Sports, Fitness and Nutrition. The attendees included professional golfer Bryson DeChambeau, who will chair the council; controversial National Football League kicker Harrison Butker; World Wrestling Entertainment mainstay Paul 'Triple H' Levesque; golfer Annika Sorenstam; and football Hall of Famer Lawrence Taylor. The Eagles running back wasn't in attendance, but will be joined by golfers Jack Nicklaus, Nelly Korda, and Gary Player (who was also awarded the Medal of Freedom alongside Sorenstam); Tony Romo, Nick Bosa, and Barkley; legendary hockey player Wayne Gretzky; and baseball player Mariano Rivera. The list also includes NFL Commissioner Roger Goodell, whom Trump repeatedly scrutinized during his first presidential term. Barkley was criticized during the off-season for spending time with President Trump on a golf outing prior to the Eagles' ring celebration.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store